Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695173 · ClinicalTrials.gov registry record
Complications of UTI in Patients on Dapagliflozin
A clinical trial of Severe Complications of Urinary Tract Infections, sponsored by AstraZeneca.
- Completed
- Registry status
- 683,380
- Enrollment target
- 3
- Study locations
NCT02695173 is a study of Severe Complications of Urinary Tract Infections that has completed, run by AstraZeneca. The registered enrollment target is 683,380 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02695173, a study of Severe Complications of Urinary Tract Infections, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 683,380 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as pyelonephritis and urosepsis, among patients with type 2 diabetes mellitus (T2DM) who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.
Conditions Studied
Study Locations (3)
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Other
- Research Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 683,380 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2020-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695173
The ClinicalTrials.gov registry entry for NCT02695173 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 683,380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Complications of Urinary Tract Infections appearing as the primary indexed condition, and to 0 interventions.
NCT02695173 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Delaware, District of Columbia, Other.
Frequently Asked Questions
What is clinical trial NCT02695173 about?
NCT02695173 is a clinical study titled "Complications of UTI in Patients on Dapagliflozin". The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as pyelonephritis and urosepsis, among patients with type 2 diabetes melli...
What is the current status of trial NCT02695173?
This trial is currently completed. The enrollment target is 683,380 participants. The study started on 2017-01-01. Estimated completion is 2020-11-30.
What conditions does trial NCT02695173 study?
This clinical trial studies the following conditions: Severe Complications of Urinary Tract Infections.
Who is sponsoring clinical trial NCT02695173?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02695173 being conducted?
This trial has 3 study locations across Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.